trial

A Positron-Emission-Tomography (PET) Study to Measure the Blockade of Dopamine Receptors (D2) in Specific Areas of the Brain in Relation to the Plasma Concentrations of Paliperidone Extended Release (ER) and Oral Risperidone in Schizophrenia Patients and Healthy Controls

NCTId NCT00934635
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Terminated
Enrollment 2 (actual)
Sponsored by Janssen-Cilag Farmaceutica Ltda.
Primary completion 2009-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Terminated
Enrollment
2 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Parallel
Masking
None
Start
2009-09
Primary completion
2009-12
Eligibility
ALL · 18 Years · 50 Years

Interventions & indications

Drugs
PaliperidoneRisperidonePET Scan

Sponsors

Janssen-Cilag Farmaceutica Ltda.Lead Sponsor

Sites

0 total

Facts & assertions

4 sourced
Enrollment
2
Phase
PHASE4
Primary Completion Date
2009-12
Status
TERMINATED
relationships
The graph out of here
drug
Paliperidone
drug
Risperidone
drug
PET Scan
drug
lead_sponsor
Janssen-Cilag Farmaceutica Ltda.
company
indication
Schizophrenia
indication
Schizophrenia
indication